MoonLake Immunotherapeutics Management
Management criteria checks 3/4
MoonLake Immunotherapeutics' CEO is Jorge da Silva, appointed in Apr 2022, has a tenure of 2.08 years. total yearly compensation is $1.20M, comprised of 48.9% salary and 51.1% bonuses, including company stock and options. directly owns 4.75% of the company’s shares, worth $122.09M. The average tenure of the management team and the board of directors is 2.1 years and 2.1 years respectively.
Key information
Jorge da Silva
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 48.9% |
| CEO tenure | 2.1yrs |
| CEO ownership | 4.8% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14
MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | US$1m | US$586k | -US$36m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$43m |
| Dec 31 2022 | US$5m | US$460k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$58m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Dec 31 2021 | US$5m | US$230k | -US$64m |
Compensation vs Market: Jorge's total compensation ($USD1.20M) is below average for companies of similar size in the US market ($USD6.70M).
Compensation vs Earnings: Jorge's compensation has been consistent with company performance over the past year.
CEO
Jorge da Silva (45 yo)
2.1yrs
Tenure
US$1,198,215
Compensation
Dr. Jorge Santos da Silva is a Co-Founder of MoonLake Immunotherapeutics (Alternate name MoonLake Immunotherapeutics AG) and has served as the Chief Executive Officer since April 2022. Dr. da Silva is a Di...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.1yrs | US$1.20m | 4.75% $ 122.1m | |
| Co-Founder & Chief Scientific Officer | 2.1yrs | US$1.23m | 4.73% $ 121.5m | |
| Chief Financial Officer | 2.1yrs | US$891.60k | 0.84% $ 21.6m | |
| Chief Technical Officer | 2.7yrs | no data | no data | |
| General Counsel | 1.4yrs | no data | no data | |
| Director of HR | less than a year | no data | no data | |
| Chief Clinical Development Officer | 2.7yrs | no data | no data |
2.1yrs
Average Tenure
45yo
Average Age
Experienced Management: MLTX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.1yrs | US$1.20m | 4.75% $ 122.1m | |
| Independent Chairman of the Board | 2.1yrs | US$315.49k | 0.55% $ 14.0m | |
| Independent Director | 2.1yrs | US$287.49k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$280.99k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$299.99k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$277.49k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$44.00k | no data |
2.1yrs
Average Tenure
51yo
Average Age
Experienced Board: MLTX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.